Quantitative prognostic indices in peritoneal carcinomatosis
Introduction
Quantitative prognostic indicators have been successfully used in several surgical disciplines and served as guidelines in the selection of treatments to maximize benefits. Often, the major value of the quantitative prognostic indicators is to exclude patients who have no chance to benefit from high risk and costly management protocols. Major requirements of a quantitative prognostic indicator are reproducibility within a defined patient population and simplicity.
Concerning peritoneal carcinomatosis, five different staging systems are available: the Lyon staging system, the Peritoneal Cancer Index (PCI), the Japanese Research Society for Gastric Cancer carcinomatosis staging (JRSGS), the Dutch simplified peritoneal carcinomatosis index (SPCI) and the Completeness of Cytoreduction Score (CCR).
Section snippets
The Lyon staging system
This staging was first described in 1994 by Gilly and coworkers and takes into account the size of malignant implants (<5 mm, 5 mm to 2 cm, >2 cm) and their distribution (localized or diffuse).1 The details of this staging system are summarized in Table 1.
This staging system can be used as the abdominal exploration is performed as well as after cytoreduction is complete, allowing a downstaging index. For example, a stage 4 peritoneal carcinomatosis which has underwent a complete macroscopic
The Peritoneal Cancer Index
The Peritoneal Cancer Index (PCI) was reported by Jacquet and Sugarbaker: it is a quantitative assessment of both cancer distribution and cancer implant size throughout the abdomen and the pelvis.7 This scoring system has been used to quantitate carcinomatosis, sarcomatosis and peritoneal mesothelioma. Two components are involved in its calculation. One component is the distribution of tumor in the abdominopelvic regions and the other component is the lesion size score. Distribution of the
The Japanese Research Society for Gastric Cancer carcinomatosis staging (JRSGC)
In Japan, carcinomatosis from gastric cancer is classified by the JRSGC as follows: P0 means no implants to the peritoneum. P1 means cancerous implants directly adjacent to the stomach peritoneum, including the greater omentum. P2 means several scattered metastases to the distant peritoneum or ovarian metastasis alone. P3 means numerous metastases to the distant peritoneum. This classification has been used in Japanese studies as an accurate quantitative prognostic indicator for gastric cancer.
The Dutch simplified peritoneal carcinomatosis assessment
At the Netherlands Institute, the extent of tumor is recorded on standardized forms indicating large (>5 cm), moderate (1–5 cm), small (<1 cm) or no involvement. The tumor distribution was recorded according to the presence of tumor deposits in seven abdominal areas: left and right subdiaphragmatic, subhepatic, omentum/transverse colon, small intestine/mesenterium, ileocecal and pelvic. This assessment has been referred to as the “simplified PCI” or SPCI. The system is routinely used for
Completeness of Cytoreduction Score (CCR)
Using UICC score for surgical resections in carcinomatosis is possible. However, in patients with peritoneal carcinomatosis, it is difficult or impossible to confirm a real R0 resection and the UICC score is “R0–R1” for complete cytoreduction and R2 for incomplete cytoreduction. This UICC score has been used in evaluation of cytoreductive surgery combined with IPCH. In a series of 56 patients with carcinomatosis from colon and ovarian cancer treated by cytoreductive surgery and IPCH, Glehen et
Discussion
One may be surprised by the number of peritoneal carcinomatosis staging system available all over the world. In fact, at least three of them are complementary ones: the Lyon staging system, the PCI and the SPCI.
The Lyon staging system and the PCI contribute to the precise intraoperative description of carcinomatosis implants within the abdominopelvic cavity. Using both of them allows an accurate “map” of the lesions. For some diagnosis of peritoneal carcinomatosis, Lyon staging system is the
References (27)
- et al.
Carcinoses péritonéales traitées par chirurgie de reduction tumorale et chimiohyperthermie intrapéritonéale
Ann Chir
(2000) - et al.
Quantitative methodologies for selection of patients with recurrent abdominopelvic sarcoma for treatment
Eur J Cancer
(1999) - et al.
Extensive cytoreductive surgery combined with intraoperative intraperitoneal perfusion with cisplatin under hyperthermic conditions (OVHI-PEC) in patients with recurrent ovarian cancer: a feasibility pilot
Eur J Surg Oncol
(2000) - et al.
Quantitative prognostic indicators of peritoneal surface malignancy: carcinomatosis, sarcomatosis and peritoneal mesothelioma
Surg Oncol Clin North Am
(2003) - et al.
Regional chemotherapy and intraoperative hyperthermia for digestive cancers with peritoneal carcinomatosis
Hepatogastroenterology
(1994) - et al.
Peritoneal carcinomatosis from non gynaecologic malignancies: results of EVOCAPE 1 multicentric prospective study
Cancer
(2000) - et al.
Study of the toxicity and results of intraperitoneal hyperthermic chemotherapy in 28 patients with peritoneal carcinomatosis
Ann Chir
(1997) - et al.
Intraperitoneal chemohyperthermia with Mitomycin C for digestive tract cancer patients with peritoneal carcinomatosis
Cancer
(2000) - et al.
Intraperitoneal chemohyperthermia with Mitomycin C in gastric cancer patients with peritoneal carcinomatosis
Anticancer Res
(1999) - et al.
Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis